Skip to content

2020

Year in Brief
Conveyer belt_action shot 2 (3).jpeg
JnJ_Texture009_Gray_RGB.png
Jacquelyn W., Senior Warehouse Operator, celebrating the first outbound shipment of the Johnson & Johnson COVID-19 vaccine.
Our New Commitments And Goals
$100 million
committed over the next five years in the U.S. to help eliminate health inequities for people of color
$800 million
committed through 2030 to advance our Healthy Lives Mission, to make our Consumer Health products more sustainable
21 ambitious
Health for Humanity 2025 Goals addressing pandemics and epidemics, global health equity, our people, planet and partners
Our Impact

People We Serve

Combating
COVID-19

Within a year, began manufacturing our single-shot COVID-19 vaccine, now authorized for emergency use by the U.S. FDA, granted a Conditional Marketing Authorization by the European Commission, and issued an Emergency Use Listing by the World Health Organization (WHO)
Advancing Breakthrough
Science for HIV

Received European Commission Marketing Authorization for REKAMBYS (rilpivirine injection) to be used with ViiV Healthcare’s Vocabria (cabotegravir injection) as the first-ever complete, long-acting injectable HIV treatment regimen
Preventing Future
Ebola Outbreaks
Received European Commission Marketing Authorization for Ebola vaccine regime11 for the prevention of Ebola Virus Disease
Expanding Access
to MDR-TB Treatment
Collaborated with the Stop TB Partnership’s Global Drug Facility to develop and implement a novel access framework for SIRTURO (bedaquiline) for 135+ low- and middle-income countries
Treating Atrial Fibrillation
Received CE mark approval for QDOT MICRO Catheter, next-generation high-power, short-duration ablation catheter for the treatment of atrial fibrillation
Partnering to Stop Smoking
As part of the Access Initiative for Quitting Tobacco, launched by the WHO to reduce smoking rates around the world, Johnson & Johnson Consumer Health donated nicotine replacement therapy patches

Employees

Over 100
medically trained employees benefited from paid leave to serve patients in their communities during the COVID-19 pandemic
Living Wage
Living Wage assessment integrated into our standard human resources processes
Ring Chart4.svg
46%
of management roles held by women globally
Ring Chart3.svg
53%
of new hires in 2020 were women

Our Credo Survey results

showed an all-time high:
people1.svg
93%
participation rate
thumbs1.svg
89%
favorability

Communities and Planets

$2.6 billion
contributed in products and cash for charitable purposes*
$50 million
additional funds committed to support frontline health workers battling
COVID-19*
windmill.svg
54% of our electricity
is produced from renewable energy sources
2010:2020.svg
45% reduction
in CO2 emissions globally since 2010
10.7% of total supplier spend
attributable to diverse suppliers
* Funded entirely by the Johnson & Johnson Foundation, a registered charity and a company limited by guarantee. The Foundation is a separate legal entity from the Johnson & Johnson Family of Companies.

Shareholders

$12.2 billion
invested in R&D, an increase of 7% over 2019
graph1.svg
59
consecutive years of dividends increases**
** Includes dividend declared in April 2021.
$7.3 billion
spent on acquisitions, creating value through innovation and partnerships

Our Recognitions

Group 161800.svg
Constituent of the FTSE4Good Index Series, designed to measure the performance of companies demonstrating strong ESG practices.
Ranked #2 for “social capital” in new The Wall Street Journal ranking of world's most sustainably managed companies.
Access to Medicine Index Logo
Ranked #3 on advancing access to medicines and technologies for people in low- and middle-income countries in the 2021 Access to Medicine Index.
Named to the 2020 CPA-Zicklin Index of Corporate Political Disclosure and Accountability for the third consecutive year with trendsetter status, indicating model corporate governance best practices.
Group 161822.svg
A List ratings from CDP in climate action for the third consecutive year and water security for the second consecutive year.
Named to the CDP supplier engagement leader board for the fourth consecutive year.
Ecovadus Trophy
Received the EcoVadis 2021 Sustainable Procurement Leadership Awards in the Best Value Chain Engagement category.
Group 161811.svg
Ranked #1 on 12th annual Gartner Healthcare Supply Chain Top 25 ranking.
Group 161805.svg
Named to Working Mother’s annual 100 Best Companies list for the 35th consecutive year, and also recognized on the Best Companies for Dads list for the third consecutive year.
Group 161821.svg
Named to Forbes 2020 list as a Best Employer for Diversity for the 2nd consecutive year.
Diversity Inc 2020 and 2019 Hall of Fame Company for Diversity.
CIO100.svg
Johnson & Johnson Technology selected as a 2021 CIO 100 Award winner for wide-ranging contributions to bringing forward Johnson & Johnson’s COVID-19 vaccine candidate.
Back to Message from Our Chairman and CEO Up next Health for Humanity Strategy & Goals
Back to Top
You are leaving jnj.com and entering a third-party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties.
Yes, let's go